Global access disparity: difference between revisions
Diff·revision 4 → 5·01:50, 9 Feb 2025
Difference between revision 4 and revision 5 of Global access disparity. 3 lines changed; the page grew by 376 bytes.
| Revision 4 — 05:04, 29 Jan 2025 AnalyticalAnnie (talk) split §Pricing from §Coverage 2,195 bytes +218 | Revision 5 — 01:50, 9 Feb 2025 OffLabelOdile (talk) attribute the affordability estimate to the analysis it comes from 2,571 bytes +376 | ||
|---|---|---|---|
| 9 | Four factors drive it. Price, set within markets rather than globally. Manufacturing capacity, which for peptides is capital-intensive and was constrained during the demand growth of the 2020s. Regulatory approval, granted jurisdiction by jurisdiction. And coverage, which determines affordability where a product is available at all.{{r|ada2024}} | 9 | Four factors drive it. Price, set within markets rather than globally. Manufacturing capacity, which for peptides is capital-intensive and was constrained during the demand growth of the 2020s. Regulatory approval, granted jurisdiction by jurisdiction. And coverage, which determines affordability where a product is available at all.{{r|ada2024}} |
| 10 | 10 | ||
| + | 11 | Disparity operates within countries as well as between them, along the ordinary lines of income and insurance status. See [[Prior authorisation]].{{r|kyle2021}} | |
| + | 12 | ||
| 11 | == Supply and manufacturing == | 13 | == Supply and manufacturing == |
| 12 | Peptide manufacture at scale requires [[Solid-phase peptide synthesis|synthesis]] capacity, [[Preparative HPLC purification|preparative chromatography]] capacity, and [[Vial filling and stoppering|fill-finish]] capacity, each of which is capital-intensive and slow to build. Demand growth outpaced all three during the period these products expanded.{{r|usp1503}} | 14 | Peptide manufacture at scale requires [[Solid-phase peptide synthesis|synthesis]] capacity, [[Preparative HPLC purification|preparative chromatography]] capacity, and [[Vial filling and stoppering|fill-finish]] capacity, each of which is capital-intensive and slow to build. Demand growth outpaced all three during the period these products expanded.{{r|usp1503}} |
| ⋮ | ⋮ | ||
| 20 | <ref name="who_obesity">World Health Organization, ''Obesity and Overweight'' fact sheet and associated global health estimates.</ref> | 22 | <ref name="who_obesity">World Health Organization, ''Obesity and Overweight'' fact sheet and associated global health estimates.</ref> |
| 21 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 23 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| + | 24 | <ref name="kyle2021">Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." ''Nursing Clinics of North America'' 56(4):635–645 (2021). PMID 34749900.</ref> | |
| 22 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> | 25 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> |
| 23 | 26 |